JP2020535232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535232A5 JP2020535232A5 JP2020538776A JP2020538776A JP2020535232A5 JP 2020535232 A5 JP2020535232 A5 JP 2020535232A5 JP 2020538776 A JP2020538776 A JP 2020538776A JP 2020538776 A JP2020538776 A JP 2020538776A JP 2020535232 A5 JP2020535232 A5 JP 2020535232A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- surfactant
- octreotide
- permeation enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 68
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 239000003961 penetration enhancing agent Substances 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 15
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 14
- 108010016076 Octreotide Proteins 0.000 claims description 14
- 229960002700 octreotide Drugs 0.000 claims description 14
- -1 glycine betaine ester Chemical class 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 229960003237 betaine Drugs 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000000693 micelle Substances 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229920000715 Mucilage Polymers 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 230000004136 fatty acid synthesis Effects 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 230000035790 physiological processes and functions Effects 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 208000020475 growth hormone-producing pituitary gland neoplasm Diseases 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010018758 Growth hormone-producing pituitary tumour Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000010430 hormone producing pituitary cancer Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024108581A JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563534P | 2017-09-26 | 2017-09-26 | |
| US62/563,534 | 2017-09-26 | ||
| PCT/US2018/052927 WO2019067596A1 (en) | 2017-09-26 | 2018-09-26 | ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING PERMEATION PROMOTERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108581A Division JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535232A JP2020535232A (ja) | 2020-12-03 |
| JP2020535232A5 true JP2020535232A5 (enExample) | 2021-11-11 |
Family
ID=63858155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538776A Pending JP2020535232A (ja) | 2017-09-26 | 2018-09-26 | 透過エンハンサーを含む送達医薬組成物 |
| JP2024108581A Pending JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108581A Pending JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190091281A1 (enExample) |
| EP (1) | EP3687508A1 (enExample) |
| JP (2) | JP2020535232A (enExample) |
| KR (1) | KR20200059269A (enExample) |
| CN (1) | CN111148512A (enExample) |
| BR (1) | BR112020005875A2 (enExample) |
| CA (1) | CA3076751A1 (enExample) |
| IL (2) | IL273477B2 (enExample) |
| WO (1) | WO2019067596A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200060748A (ko) * | 2017-09-27 | 2020-06-01 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 및 프로드러그 조성물 |
| JP7365409B2 (ja) | 2018-06-28 | 2023-10-19 | エイアールエックス エルエルシー | 溶解性単位用量膜構造物を製造するための分配方法 |
| US12440472B2 (en) * | 2021-06-16 | 2025-10-14 | Intelgenx Corp. | Stable tryptamine oral films |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2193891B (en) * | 1986-08-18 | 1990-07-25 | Sandoz Ltd | Nasal pharmaceutical composition containing a somatostatin anologue. |
| GB8620035D0 (en) * | 1986-08-18 | 1986-10-01 | Sandoz Ltd | Organic compounds |
| US5879690A (en) * | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| SE0302924D0 (sv) * | 2003-11-05 | 2003-11-05 | Camurus Ab | Pharmaceutical composition having a cationic excipient |
| US20110257096A1 (en) * | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20060073173A1 (en) * | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
| KR20130114229A (ko) * | 2005-06-03 | 2013-10-16 | 애크럭스 디디에스 피티와이 리미티드 | 경피 약물 전달 방법 및 조성물 |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| US20110311621A1 (en) * | 2010-03-16 | 2011-12-22 | Paul Salama | Pharmaceutical compositions and methods of delvery |
| IE20100174A1 (en) * | 2010-03-25 | 2012-02-29 | Trinity College Dublin | Transdermal administration of peptides |
| US9808418B2 (en) * | 2010-11-26 | 2017-11-07 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
| CN104519869A (zh) * | 2012-07-06 | 2015-04-15 | 利奥制药有限公司 | 用于递送活性成分至皮肤的包含成膜聚合物的局部组合物 |
| FR3013589B1 (fr) * | 2013-11-28 | 2017-03-31 | Soc D'exploitation De Produits Pour Les Ind Chimiques Seppic | Composition d'alkyl polyglucosides et d'acides gras cationisees |
| WO2017072774A1 (en) * | 2015-10-29 | 2017-05-04 | Solubest Ltd | Pharmaceutical compositions for transmucosal delivery |
-
2018
- 2018-09-26 EP EP18786579.5A patent/EP3687508A1/en active Pending
- 2018-09-26 CA CA3076751A patent/CA3076751A1/en active Pending
- 2018-09-26 CN CN201880062678.9A patent/CN111148512A/zh active Pending
- 2018-09-26 IL IL273477A patent/IL273477B2/en unknown
- 2018-09-26 KR KR1020207011909A patent/KR20200059269A/ko active Pending
- 2018-09-26 US US16/143,036 patent/US20190091281A1/en active Pending
- 2018-09-26 BR BR112020005875-0A patent/BR112020005875A2/pt unknown
- 2018-09-26 JP JP2020538776A patent/JP2020535232A/ja active Pending
- 2018-09-26 WO PCT/US2018/052927 patent/WO2019067596A1/en not_active Ceased
- 2018-09-26 IL IL311142A patent/IL311142A/en unknown
-
2024
- 2024-07-05 JP JP2024108581A patent/JP2024156672A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2127805C (en) | Composition for nasal administration | |
| ES2834006T3 (es) | Preparados farmacéuticos a base de lípidos para aplicación tópica | |
| JP2020535232A5 (enExample) | ||
| EP2673000B1 (en) | Polymer-carbohydrate-lipid conjugates | |
| AU2011227083B2 (en) | Stable bortezomib formulations | |
| AU2012215383B2 (en) | Novel antifungal composition | |
| CA2433037A1 (en) | Sustained-release preparation | |
| WO1988004556A1 (en) | Nasal formulations and a process for preparation thereof | |
| US20130267585A1 (en) | Pharmaceutical composition having a cationic excipient | |
| EP1317921A1 (fr) | Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations | |
| HUP9902655A2 (hu) | Sündisznófehérjéket tartalmazó gyógyászati készítmény és felhasználása | |
| EP2828297A1 (fr) | Oligosaccharides fonctionnalisés | |
| EP2920200A1 (fr) | Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques | |
| JP2004515228A (ja) | 細胞への導入を容易にするジェミニ型のペプチド系界面活性化合物 | |
| RU2004133349A (ru) | Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата | |
| IL273477B1 (en) | Administration of pharmaceutical preparations including penetration enhancers | |
| JPWO2007136134A1 (ja) | 疎水性薬物内包ポリマーミセルの製造方法 | |
| CN101450213A (zh) | 大豆蛋白药物凝胶剂及其制备方法 | |
| IL175805A0 (en) | Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof | |
| CN100371018C (zh) | 降钙素组合物 | |
| Paolino et al. | Polymers-based devices for dermal and transdermal delivery | |
| JPH0691820B2 (ja) | アミノアシラ−ゼ溶液の安定化法 | |
| WO2008068885A1 (ja) | 凍結乾燥用保護剤及び生理活性物質の製造方法 | |
| HK40008037A (en) | Novel antifungal composition | |
| EP3377038A1 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique |